Receive alerts
Unlisted (UK)
Market Cap:
52 weeks high
52 weeks low

In brief

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform.

Arecor is leveraging this platform to (i) develop a portfolio of proprietary products for diabetes care and (ii) deliver superior reformulations of its partners proprietary products.

Deep dive We explore the investor case for growth companies


Arecor is waiting for the results from phase I clinical trials of its ultra-rapid acting insulin candidate, AT247, expected by the end of the year

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Arecor punches above its weight with trials for fast-acting diabetes drugs

Investors are placing bets on a small British biotech to rival big pharma as it pushes its first diabetes drug through clinical trials

4 weeks ago